BioSpace News Archive

Transgene (Euronext Paris: TNG) (Paris:TNG), and NEC Corporation (NEC; TSE: 6701), today announce positive preliminary immunogenicity and clinical data on TG4050, their jointly developed individualized neoantigen cancer vaccine.

Pharnext SA announces the appointment of Dr. Burkhard Blank as Chief Medical Officer and Head of Research & Development effective January 1, 2022.

AB Science SA (Euronext - FR0010557264 - AB) today announces that its Phase I/II study (AB18001) evaluating AB8939 in patients with refractory and relapsed AML and refractory myelodysplastic syndrome (MDS) has received Investigational New Drug (IND) approval by the U.S. Food and Drug Administration (FDA).

NYU Langone Health announced the receipt of a $166 million gift from the Bezos Family to galvanize the health and wellness of diverse populations across the NYU Langone Hospital—Brooklyn community.

Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies, today announced that it will be participating in the 4th Annual Evercore ISI HealthconX Conference from November 30th to December 2nd, 2021.

Qynapse Inc., a medical technology company commercializing an artificial intelligence (AI)-powered neuroimaging software platform for central nervous system (CNS) disorders, will unveil its new brand and latest AI developments as a key exhibitor in the AI Showcase at the 107th Radiology Society of North America (RSNA) Annual Meeting.

Applied BioCode announced that it has released 28 Fungal Analyte Specific Reagents for use in molecular tests.

AEGEA Biotechnologies, Inc., an innovative life science company with an extensive portfolio of next-generation nucleic acid technologies, announces that the new PCR-based COVID-19 assay it designed has been validated by Biocept, Inc., a leading provider of molecular diagnostic assays, products and services.

Astrocyte Pharmaceuticals Inc., today announced the publication of a manuscript in the peer reviewed journal Stroke entitled: Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke.

Sorrento Therapeutics, Inc. announced its subsidiary, Sorrento Therapeutics Mexico, has executed a contract with a leading local distributor for the sale and distribution of up to 5 million COVI-STIX™ tests for the Mexican market.